Evogene Reports Q3 2026 Financial Results with Decreased Revenue and Increased Net Loss

Evogene (EVGN) reported its third-quarter 2026 financial results, characterized by a significant decline in revenue and an increase in net losses compared to the previous year. Quarterly revenue fell to $0.1 million from $0.3 million in the prior year, primarily due to the expiration of a collaboration agreement with Bayer in May 2026. The company also saw lower seed sales through its Casterra subsidiary. The quarterly net loss widened to $2.9 million, compared to a net income of $5.2 million in the same period last year, which had been bolstered by an ICL transaction. Despite these headwinds, management highlighted progress in their AgPlenus fungicide program and internal drug discovery efforts, noting high biological potency in lead compounds and efficacy against resistant fungal strains.

By Motley Fool Transcribing · Motley Fool ·

Evogene Reports Q3 2026 Financial Results with Decreased Revenue and Increased Net Loss

Tickers: $BAYRY $EVGN $ICL

Topics: cash burn financial results net loss R&D expenses revenue decrease

Read the full article at Motley Fool

More World news